As shown in Figure 7d, the knockdown of XRCC4 significantly attenuated the tumor growth relative to the control under the treatment of cisplatin, suggesting XRCC4 loss sensitizing cisplatin treatment in vivo. The gene discussed is XRCC4; the disease is neoplasm.